Catalog No.S2660

MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.

Price Stock Quantity  
USD 480 In stock
USD 270 In stock
USD 370 In stock
USD 970 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-0752 Chemical Structure

MK-0752 Chemical Structure
Molecular Weight: 442.9

Validation & Quality Control

1 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Gamma-secretase Inhibitors with Unique Features

  • Pan Gamma-secretase Inhibitor

    Semagacestat (LY450139) Aβ42, IC50=10.9 nM; Aβ40, IC50=12.1 nM; Aβ38, IC50=12.0 nM.

  • Most Potent Gamma-secretase Inhibitor

    LY411575 γ-secretase, IC50=0.078 nM.

  • Gamma-secretase Inhibitor in Clinical Trial

    Semagacestat (LY450139) Phase III for Alzheimer's Disease.

  • Newest Gamma-secretase Inhibitor

    FLI-06 Novel inhibitor of Notch signaling with EC50 of 2.3 μM.

Product Information

  • Compare Gamma-secretase Inhibitors
    Compare Gamma-secretase Products
  • Research Area

Product Description

Biological Activity

Description MK-0752 is a moderately potent γ-secretase inhibitor, which reduces Aβ40 production with IC50 of 5 nM. Phase 1/2.
Targets γ secretase(Aβ40) [1] [1]
IC50 5 nM
In vitro MK-0752 is identified as a moderately potent γ-secretase inhibitor, which reduces Aβ40 in a dose-dependent manner with an IC50 of 5 nM in human SH-SY5Y cells. [1] In vitro, MK-0752 blocks Notch-intracellular domain (ICD) cleavage and its subsequent nuclear translocation. [2]
In vivo MK-0752 (240 mg/kg) reduces the generation of newly produced Aβ with 90% decrease of AUV in the brain of rhesus monkeys. In addition, MK-0752 treatment increases levels of Aβ 1-14, Aβ 1-15, and Aβ 1-16 , while decreases levels of Aβ 1-17. [1] In guinea-pigs, oral administration of MK-0752 (10 mg/kg -30 mg/kg) results in the dose-dependent reduction of Aβ40 in plasma, brain and cerebrospinal fluid (CSF) with IC50 of 440 nM in brain. [2]
Features A moderately potent γ-secretase inhibitor.

Protocol(Only for Reference)

Animal Study: [1]

Animal Models Cisterna Magna Ported (CMP) Rhesus Monkey Model.
Formulation MK-0752 is dissolved in water.
Dosages ≤240 mg/kg
Administration Administered via p.o.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)
Body Surface Area (m2)0.0070.0250.
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)


[1] Cook JJ, et al. J Neurosci, 2010, 30(19), 6743-6750.

[2] Harrison H, et al. Cancer Res, 2010, 70(2), 709-718.

Clinical Trial Information( data from, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
Start Date Phases
NCT01295632 Completed Advanced Cancer Merck Sharp & Dohme Corp. February 2011 Phase 1
NCT01243762 Terminated Neoplasms Malignant Merck Sharp & Dohme Corp. November 2010 Phase 1
NCT01098344 Completed Pancreatic Cancer Cancer Research UK April 2010 Phase 1
NCT00803894 Completed Healthy Merck Sharp & Dohme Corp. December 2008 Phase 1
NCT00572182 Terminated Brain and Central Nervous System Tumors Pediatric Brain Tumor Consortium|National Cancer Institut  ...more Pediatric Brain Tumor Consortium|National Cancer Institute (NCI) July 2008 Phase 1

view more

Chemical Information

Download MK-0752 SDF
Molecular Weight (MW) 442.9


CAS No. 471905-41-6
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 89 mg/mL (200.94 mM)
Ethanol 45 mg/mL (101.6 mM)
Water <1 mg/mL
In vivo 30% propylene glycol, 5% Tween 80, 65% D5W 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Gamma-secretase Products

  • PF-03084014 (PF-3084014)

    PF-03084014 (PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Phase 2.

  • AZD3839

    AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.

  • Xanthohumol

    Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Phase 1.

  • Avagacestat (BMS-708163)

    Avagacestat (BMS-708163) is a potent, selective, orally bioavailable γ-secretase inhibitor of Aβ40 and Aβ42 with IC50 of 0.3 nM and 0.27 nM, demonstrating a 193-fold selectivity against Notch. Phase 2.

    Features:Appears to be more “notch sparing” than semagacestat (LY450139).

  • RO4929097

    RO4929097 is a γ secretase inhibitor with IC50 of 4 nM in a cell-free assay, inhibiting cellular processing of Aβ40 and Notch with EC50 of 14 nM and 5 nM, respectively. Phase 2.

  • Semagacestat (LY450139)

    Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM in H4 human glioma cell. Phase 3.

    Features:The best characterized γ-secretase inhibitor that has reached the clinic.


    DAPT (GSI-IX) is a novel γ-secretase inhibitor, which inhibits Aβ production with IC50 of 20 nM in HEK 293 cells.

  • LY411575

    LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch cleavage with IC50 of 0.39 nM in APP or NΔE expressing HEK293 cells.

  • YO-01027 (Dibenzazepine)

    YO-01027 (Dibenzazepine) is a dipeptidic γ-secretase inhibitor with IC50 of 2.6 nM and 2.9 nM in cell-free assays for APPL and Notch cleavage, respectively.

  • FLI-06

    FLI-06 is a novel inhibitor of Notch signaling with EC50 of 2.3 μM.

Recently Viewed Items

Tags: buy MK-0752 | MK-0752 supplier | purchase MK-0752 | MK-0752 cost | MK-0752 manufacturer | order MK-0752 | MK-0752 distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us